ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
A Novel Activatable Nanoradiosensitizer for Second Near-Infrared Fluorescence Imaging-Guided Safe-Dose Synergetic Chemo-Radiotherapy of Rheumatoid Arthritis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Near-infrared II fluorescence imaging of PD-L1 and VEGF for assessing and early prediction of "T+A" therapeutic responsiveness in hepatocellular carcinoma.Materials today. Bio · 2026Article
- DOTA-grafted Cationic Polymers Behaving as Powerful Macromolecular Resistance-reversal Agents (MRRAs) Combating Against New Delhi Metallo-β-lactamase (NDM)-producing Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.Materials today. Bio · 2026Review
- Xuetongsu attenuates bone destruction in rheumatoid arthritis by suppressing RANKL/RANK/NFATc1 pathway to inhibit osteoclastogenesis and bone resorption.Bone & joint research · 2025Article
- Janus Ag/Fe-HfOMaterials today. Bio · 2025Article
- pH-responsive nanovesicles capable of remodeling the tumor microenvironment enable activatable near-infrared-II fluorescence image-guided enhanced radiotherapy.Materials today. Bio · 2025Article
- Biomimetic Nanoplatform for Targeted Rheumatoid Arthritis Therapy: Modulating Macrophage Niches Through Self-Sustaining Positive Feedback-Driven Drug Release Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Selenium Attenuates Radiation Colitis by Regulating cGAS-STING Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges.Journal of nanobiotechnology · 2024Review
- A Novel Activatable Nanoradiosensitizer for Second Near-Infrared Fluorescence Imaging-Guided Safe-Dose Synergetic Chemo-Radiotherapy of Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Modularized supramolecular assemblies for hypoxia-activatable fluorescent visualization and image-guided theranostics.Theranostics · 2024Article
- Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The precise theranostics of rheumatoid arthritis (RA) remains a formidable challenge in clinical practice. Exploring novel applications of contemporary therapeutic approaches like chemo-radiotherapy is promising as a highly effective strategy for RA. Herein, a novel activatable nanoradiosensitizer-40 (denoted as IRnR-40) is developed, based on encapsulating the clinically approved drugs cisplatin (DDP) and indocyanine green (ICG) within a gelatin shell to achieve second near-infrared fluorescence (NIR-II FL) imaging-guided safe-dose synergetic chemo-radiotherapy. The high concentration of matrix metalloproteinase-9 (MMP-9) in the RA microenvironment plays a pivotal role in triggering the responsive degradation of IRnR-40, leading to the rapid release of functional molecules DDP and ICG. The released ICG serves the dual purpose of illuminating the inflamed joints to facilitate accurate target volume delineation for guiding radiotherapy, as well as acting as a real-time reporter for quantifying the release of DDP to monitor efficacy. Meanwhile, the released DDP achieves highly effective synergistic chemotherapy and radiosensitization for RA via the dual reactive oxygen species (ROS)-mediated mitochondrial apoptotic pathway. To sum up, this activatable nanoradiosensitizer IRnR-40 is believed to be the first attempt to achieve efficient NIR-II FL imaging-guided safe-dose chemo-radiotherapy for RA, which provides a new paradigm for precise theranostics of refractory benign diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.